Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02149446
Other study ID # Surgisis-001
Secondary ID
Status Recruiting
Phase N/A
First received May 21, 2014
Last updated March 31, 2015
Start date April 2014
Est. completion date December 2016

Study information

Verified date March 2015
Source Karolinska University Hospital
Contact John Blomberg, MD, PhD
Email john.blomberg@karolinska.se
Is FDA regulated No
Health authority Sweden: Medical Products Agency
Study type Interventional

Clinical Trial Summary

Dividing pancreas when performing left-sided resections opens the risk for leakage from the divided end of the pancreas. Pancreatic juices could have a severe effect on surrounding abdominal tissues with abscess formation producing systemic inflammation and potential lethal bleeding.

Studies have shown that reinforcement of the staple line when dividing pancreas could reduce the risk of leakage.

Surgisis (COOK Medical) a product already in use for staple line reinforcement in gastric and lung surgery could be used as a reinforcement when stapling pancreas in left sided resections.

In a prospective randomized trial we want to compare Surgisis reinforcement to no reinforcement of stapled division in left sided pancreatic resections.

Primary outcome is pancreatic fistula yes/no.


Description:

Resection of the distal pancreas is often done due to a localized tumor in the body or tail of the pancreas. During later years the mortality after pancreatic resections have been reduced but there still is a substantial risk of severe complications mainly due to leakage from the pancreatic division line which could lead to suffering, longer hospital stay, higher costs and sometimes death. Leakage from a tail resection is probably more common than thought of before. Frequencies of above 30% and even up to 60% have been reported.

The use of somatostatin to reduce the production of pancreatic juice or comparison between stapled division, suturing of the remaining part of the cut pancreas or covering it with glue or available surrounding tissue have not showed significant superiority for any of these methods except for a positive trend regarding the stapling technique. Staple line reinforcement with resorbable mesh has in some studies showed a both negative and positive effect on pancreatic fistula frequency. These studies have been small and non-randomized. A larger randomized single blinded study by Hamilton et al on the other hand showed a significant positive effect on pancreatic fistula frequency after distal pancreatic resection using an absorbable reinforcement device put on the stapler, when only regarding type B and C fistulas as defined by the ISGPF (International Study Group on Pancreatic Fistula) pancreatic leak grading system.

Although all these endeavors the problem of pancreatic fistulas remain and therefore all these operations are concluded with the deposit of one or more drains to the area of the cut pancreas.

There is therefore of importance to continue the work of reducing complications in high risk pancreatic surgery using scientific procedures of high quality as in blinded randomized controlled trials (RCT). The use of reinforced stapling techniques has been used in lung surgery and bariatric surgery to reduce air leakage and strengthen anastomoses. The material used is processed submucosa from the small bowel of the pig, produced by COOK© Medical to fit endoscopic staplers from Ethicon© or Covidien©.

After the promising result from Hamilton et al we plan to study if the reinforcement made by COOK© could reduce the frequency of pancreatic fistula after stapled distal pancreatic surgery in a single blinded RCT.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 2016
Est. primary completion date November 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Every patient eligible for pancreatic tail resection.

Exclusion Criteria:

- Not able to read Swedish.

- Not able to understand or accept the concept.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Surgisis (C-SLRA-ECH60) made by COOK Medical
Surgisis is extracellular matrix collagen made of the submucosal layer of pigs intestines. Surgisis is gradually remodeled, leaving behind organized tissue

Locations

Country Name City State
Sweden Dep of Surgical Gastroenterology, Karolinska University Hospital Stockholm

Sponsors (5)

Lead Sponsor Collaborator
Karolinska University Hospital Lund University Hospital, Norrlands University Hospital, Sahlgren´s University Hospital, University Hospital, Linkoeping

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Post operative pancreatic fistula (POPF), Y/N Pancreatic amylase concentration in any post operative drains. Fistula is diagnosed if pancreatic amylase > 3 times the upper normal limit of pancreatic amylase in plasma on post operative day 3 or later Participants will be followed for the duration of hospital stay, an expected average of 2 weeks No
Secondary POPF healing time Time from diagnosis to healed pancreatic fistula Participants will be followed for the duration of hospital stay, an expected average of 2 weeks No
Secondary POPF grade according to International Study Group of Pancreatic Fistula (ISGPF) grade A/B/C Worst POPF grade registered during the observation period. Participants will be followed for the duration of hospital stay, an expected average of 2 weeks No
Secondary Blood chemistry During the first 7 post operative days each participant will have daily measurements taken from blood samples regarding C-reactive protein, white blood count, pancreatic plasma amylase and from drain fluid regarding pancreas amylase. The participants daily drain volume will also be measured. The first 7 days after operation No
Secondary Morbidity According to Clavien scoring Participants will be followed for the duration of hospital stay, an expected average of 2 weeks. No
Secondary Mortality < 90 days after the operation No
Secondary Hospital stay Number of days Participants will be followed for the duration of hospital stay, an expected average of 2 weeks. No
See also
  Status Clinical Trial Phase
Completed NCT03891225 - Efficacy of Amniotic Membrane Over Pancreatic Anastomosis After Pancreaticoduodenenctomy to Preventing Pancreatic Fistula Phase 1
Completed NCT05291923 - Predictors of Severity of Postoperative Pancreatic Fistula After Pancreatoduodenectomy